Treatment with immune checkpoint inhibitors, such as anti-PD1, anti-PD-L1, anti-CTLA-4, and anti-LAG3, in the setting of late-stage melanoma has significantly improved the long-term survival of patients vs. previous standard-of-care therapies. The gene discussed is CTLA4; the disease is melanoma.